Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Scientific Reports, 12, 1, S. 11846-
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2022
- Ereignis
-
Veröffentlichung
- (wer)
-
Springer Science and Business Media LLC
- (wann)
-
2022
- Urheber
-
Schlack, Katrin
Seitzer, Konstantin
Wüstmann, Neele
Humberg, Verena
Grundmann, Norbert
Steinestel, Julie
Tiedje, Dorothee
Rahbar, Kambiz
Krabbe, Laura-Maria
Bögemann, Martin
Schrader, Andres J.
Bernemann, Christof
- DOI
-
10.1038/s41598-022-16094-6
- URN
-
urn:nbn:de:bvb:384-opus4-974550
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:49 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schlack, Katrin
- Seitzer, Konstantin
- Wüstmann, Neele
- Humberg, Verena
- Grundmann, Norbert
- Steinestel, Julie
- Tiedje, Dorothee
- Rahbar, Kambiz
- Krabbe, Laura-Maria
- Bögemann, Martin
- Schrader, Andres J.
- Bernemann, Christof
- Universität Augsburg
- Springer Science and Business Media LLC
Entstanden
- 2022
Ähnliche Objekte (12)
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience